SYNGENE

Valuation ratios • P/E 50–60 — relatively high compared to many pharma stocks. • PB 5x — also on the richer side. Earnings & profit trends • Company has shown positive earnings and profits in recent quarters, with profitability expanding in some periods. • However, some metrics like net income growth show mixed momentum, with slight YoY income dips in data feeds. Balance sheet snapshot • Strong net cash position with cash significantly above debt levels — a positive. • Operational cashflow and free cash conversion appear healthy. Dividend yield • Dividend yield 0.2 % — modest income return.